FDA GRANTS FAST TRACK DESIGNATION TO CTI BIOPHARMA’S PACRITINIB, A NOVEL JAK2 INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS

  • MPNRF | April 30, 2021

    August 5, 2014

    CTI BioPharma has been granted Fast Track designation by the FDA for pacritinib for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are not as well managed on other JAK2 therapy. Pacritinib is currently in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis.

    Click here to read the press release.